Skip to main content

Advertisement

SpringerLink
Log in

Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Indoleamine 2,3-dioxygenase (IDO), a catabolizing enzyme of tryptophan, is a novel immunosuppressive agent blocking T-cell activation in neoplastic cells, including acute myeloid leukemia (AML) cells. IDO inhibitors as 1-methyl tryptophan (1MT) can abrogate IDO enzymatic activity and may result in an effective immune response. Mononuclear cells (MNCs) were separated from peripheral blood of 25 AML patients and 25 normal adults. IDO expression was detected by RT-PCR and its enzymatic activity by a colorimetric method. MNCs were cultured and the effects of Adriamycin, 1MT and a mixture of both on blast and lymphocyte cell counts after 24 and 72 h were detected. IDO mRNA and activity were detected in 52% of patients and absent in normal subjects. There was a significant correlation between IDO mRNA expression and its enzymatic activity in AML. IDO activity was correlated positively with patient’s ages and negatively with hemoglobin levels. There was a significant inhibition of blast cells proliferation with Adriamycin and more inhibition when combined with 1MT. The inhibition was more after 72 h more than 24 h of culture. However, using 1MT alone showed no significant inhibitory effect on blast cells, with a significant increase in lymphocyte counts. Our study confirms the role of indoleamine 2,3-dioxygenase in tumor-induced immune tolerance and points to the possible benefit of 1-methyl tryptophan as immunotherapeutic enhancing the anticancer effects of traditional chemotherapeutics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Liu X, Newton RC, Friedman SM, Scherle PA. Indoleamine 2, 3-dioxygenase, an emerging target for anti-cancer therapy. Curr Cancer Drug Targets. 2009;9:938–52.

    Article  PubMed  CAS  Google Scholar 

  2. Uyttenhove C, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med. 2003;9:1269–74.

    Article  PubMed  CAS  Google Scholar 

  3. Curti A, et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25− into CD25+ T regulatory cells. Blood. 2007;109(7):2871–7.

    PubMed  CAS  Google Scholar 

  4. Corm S, et al. Indoleamine 2, 3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients’ sera by HPLC and is inducible by IFN-gamma. Leuk Res. 2009;33(3):490–4.

    Article  PubMed  CAS  Google Scholar 

  5. Mellor AL, et al. Tryptophan catabolism and T cell responses. Adv Exp Med Biol. 2003;527:27–35.

    PubMed  CAS  Google Scholar 

  6. Frumento G, et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med. 2002;196:459–68.

    Article  PubMed  CAS  Google Scholar 

  7. Chiesa MD, et al. The tryptophan catabolite l-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood. 2006;108:4118–25.

    Article  PubMed  Google Scholar 

  8. Wang J. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem. 2006;281:22021–8.

    Article  PubMed  CAS  Google Scholar 

  9. Ino K, et al. Indoleamine 2, 3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer. 2006;95:1555–61.

    Article  PubMed  CAS  Google Scholar 

  10. Brandacher G, et al. Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: impact on tumor-infiltrating cells. Clin Cancer Res. 2006;12:1144–51.

    Article  PubMed  CAS  Google Scholar 

  11. Munn DH, Mellor AL. The tumor-draining lymph node as an immune privileged site. Immunol Rev. 2006;213:146–58.

    Article  PubMed  Google Scholar 

  12. Mckenzie SB. Advances in understanding the biology and genetics of acute myeloid leukemia. Clin Lab Sci. 2005;18:28–37.

    PubMed  Google Scholar 

  13. Tang XQ, et al. Indoleamine 2, 3- dioxygenase activity in acute myeloid leukemia cells contributing to tumor immune escape. J Exp Hematol/Chin Assoc Pathophysiol. 2006;14(3):539–42.

    CAS  Google Scholar 

  14. Curti A, et al. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2, 3-dioxygenase. Leukemia. 2007;21:353–5.

    Article  PubMed  CAS  Google Scholar 

  15. Chamuleau MED, et al. High INDO (indoleamine 2, 3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica. 2008;93:1894–8.

    Article  PubMed  CAS  Google Scholar 

  16. Nilsson C, et al. Optimal blood mononuclear cell isolation procedures for gamma interferon enzyme-linked immunospot testing of healthy swedish and tanzanian subjects. Clin Vaccine Immunol. 2008;15(4):585–9.

    Article  PubMed  CAS  Google Scholar 

  17. Daubener W, et al. A new simple bioassay for human IFN-gamma. J Immunol Methods. 1994;168:39–47.

    Article  PubMed  CAS  Google Scholar 

  18. Bradford MA. A rapid and sensitive method for the quantition of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem. 1976;72:248–54.

    Article  PubMed  CAS  Google Scholar 

  19. Kudo Y, Boyd CA. The role of l-tryptophan transport in l-tryptophan degradation by indoleamine 2, 3-dioxygenase in human placental explants. J Physiol. 2001;531(2):417–23.

    Article  PubMed  CAS  Google Scholar 

  20. Curti A, Trabanelli S, Salvestrini V, Baccarani M, Lemoli RM. The role of indoleamine 2, 3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood. 2009;113(11):2394–401.

    Article  PubMed  CAS  Google Scholar 

  21. Broomfield S, et al. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res. 2005;65:7580–4.

    PubMed  CAS  Google Scholar 

  22. Dummer W, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest. 2002;110:185–92.

    PubMed  CAS  Google Scholar 

  23. King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell. 2004;117:265–77.

    Article  PubMed  CAS  Google Scholar 

  24. Brown IE, Blank C, Kline J, Kacha AK, Gajewski TF. Homeostatic proliferation as an isolated variable reverses CD8+ T Cell anergy and promotes tumor rejection. J Immunol. 2006;177:4521–9.

    PubMed  CAS  Google Scholar 

  25. Beyer M, et al. Reduced frequencies and suppressive function of CD4+ CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood. 2005;106:2018–25.

    Article  PubMed  CAS  Google Scholar 

  26. Munn DH, et al. Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004;114:280–90.

    PubMed  CAS  Google Scholar 

  27. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005;11:312–9.

    Article  PubMed  CAS  Google Scholar 

  28. Friberg M, et al. Indoleamine 2, 3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer. 2002;101:151–5.

    Article  PubMed  CAS  Google Scholar 

  29. Zeng J, et al. Prevention of spontaneous tumor development in a ret transgenic Mouse model by ret peptide vaccination with indoleamine 2, 3-dioxygenase inhibitor 1-methyl tryptophan. Cancer Res. 2009;69(9):3963–70.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Biochemistry & Molecular Biology, Faculty of Medicine, Ain Shams University, Abbasia, Cairo, Egypt

    Noura M. El Kholy, Maha M. Sallam, Manal B. Ahmed, Reem M. Sallam & Haidy Z. Habib

  2. Department of Internal Medicine and Clinical Hematology, Ain Shams University, Cairo, Egypt

    Inas A. Asfour

  3. Department of Histology, Ain Shams University, Cairo, Egypt

    Jehad A. Hammouda

  4. Medical Research Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    Fatima Abu-Zahra

Authors
  1. Noura M. El Kholy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maha M. Sallam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manal B. Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Reem M. Sallam
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Inas A. Asfour
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jehad A. Hammouda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Haidy Z. Habib
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fatima Abu-Zahra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maha M. Sallam.

Rights and permissions

Reprints and permissions

About this article

Cite this article

El Kholy, N.M., Sallam, M.M., Ahmed, M.B. et al. Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells. Med Oncol 28, 270–278 (2011). https://doi.org/10.1007/s12032-010-9459-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9459-6

Keywords

Search

Navigation